January 12, 2015 — Transcatheter Technologies GmbH has announced that it is expanding its product family to include Tresillo, a transcatheter mitral valve implantation (TMVI) version. Tresillo joins the product Trinity, a repositionable transcatheter aortic valve implantation (TAVI) system for transapical and transfemoral implantation.
Approximately 3 percent of the population older than 60 years is suffering from symptomatic mitral valve regurgitation and may benefit from a Transcatheter mitral valve implantation while avoiding open-heart surgery.
The Trinity and Tresillo systems are not approved for sale or investigational use in the United States.
For more information: www.transcatheter-technologies.com
April 17, 2024 
